van Sandick Johanna W, van Lanschot J Jan B, ten Kate Fiebo J W, Tijssen Jan G P, Obertop Hugo
Department of Surgery, Academic Medical Center, University of Amsterdam, The Netherlands.
J Am Coll Surg. 2002 Jan;194(1):28-36. doi: 10.1016/s1072-7515(01)01119-x.
Various techniques have been described for the surgical treatment of esophageal cancer. The transhiatal approach has been debated for its safety and oncologic results.
Between January 1993 and September 1996, 115 patients underwent a transhiatal esophagectomy with curative intent for adenocarcinoma or squamous cell carcinoma of the middle or distal esophagus or esophagogastric junction. Procedure-related hazards, pathologic results, and prognostic factors for survival were evaluated. Median duration of postoperative followup was 27 months (range 1 to 74 months) for all patients and 45 months (range 30 to 74 months) for those alive at final followup.
No emergency thoracotomies were experienced. In-hospital mortality was 3.5%. Vocal cord dysfunction (24%) and pulmonary complications (23%) were the most frequent early postoperative complications. A microscopically radical resection was achieved in 73% of patients. Overall survival was 45% at 3 years. In univariate analysis, the most pronounced indicators of longterm survival (p < 0.0001) were radicality of the resection, lymph node involvement, lymph node ratio (ie, the ratio of invaded to removed lymph nodes), and pathologic tumor stage. Multivariate analysis identified the lymph node ratio (p < 0.0001) as the strongest independent predictor of long-term survival, followed by radicality of the resection (p = 0.0064) and duration of ICU stay (p = 0.027).
Transhiatal esophagectomy without thoracotomy can be considered a safe procedure for resectable cancer of the midesophagus, distal esophagus, or esophagogastric junction. Radicality and survival results were in line with the data reported for traditional transthoracic approaches. A prognostic value of the lymph node ratio was observed. It emphasizes the need for controlled trials aimed at delineating the prognostic impact of an extended lymph node dissection.
食管癌的手术治疗已有多种技术被描述。经裂孔手术因其安全性和肿瘤学效果一直存在争议。
1993年1月至1996年9月期间,115例患者因食管中下段或食管胃交界部腺癌或鳞状细胞癌接受了根治性经裂孔食管切除术。评估了与手术相关的风险、病理结果和生存预后因素。所有患者术后中位随访时间为27个月(范围1至74个月),最后随访时仍存活的患者为45个月(范围30至74个月)。
未进行急诊开胸手术。住院死亡率为3.5%。声带功能障碍(24%)和肺部并发症(23%)是最常见的术后早期并发症。73%的患者实现了显微镜下根治性切除。3年总生存率为45%。单因素分析中,长期生存的最显著指标(p < 0.0001)是切除的根治性、淋巴结受累情况、淋巴结比率(即受累淋巴结与切除淋巴结的比率)和病理肿瘤分期。多因素分析确定淋巴结比率(p < 0.0001)是长期生存的最强独立预测因素,其次是切除的根治性(p = 0.0064)和重症监护病房停留时间(p = 0.027)。
对于可切除的食管中段、下段或食管胃交界部癌,经裂孔食管切除术可被视为一种安全的手术方法。根治性和生存结果与传统开胸手术报道的数据一致。观察到淋巴结比率具有预后价值。这强调了开展对照试验以明确扩大淋巴结清扫的预后影响的必要性。